Using the app, biopharmaceutical developers can break through the data wrangling and programming challenges associated with the analysis of large-scale, single-cell datasets.
The REVEAL: Single Cell app from Paradigm4, a provider of scientific information solutions, allows for biopharmaceutical developers to address the data wrangling and programming challenges associated with the analysis of large-scale, single-cell datasets.
Using Paradigm4’s Agile Science engine, SciDB, the app uses vectors and multidimensional arrays to support scientific data modeling, storage, and large-scale computation. Its elastic computing platform is a parallel, transaction-safe, array-oriented, analytics solution which offers users access to disease biology, samples from patients with more cells, key biological hypotheses for target evaluation, disease progression, and precision medicine.
Additionally, users have the ability to select cells of interest across all studies using individual metadata tags to assess tissue distribution, variance in response to treatment, and for comparisons of normal to diseased cells. Datasets can also be organized according to individual users’ data models.
“When Covid-19 hit earlier this year, we used our REVEAL: Single Cell app to identify tissues expressing the key SARS-CoV-2 entry associated genes in seconds,” said Zachary Pitluk, vice-president of Life Sciences and Healthcare at Paradigm4, in a Sept. 15, 2020 press release. “We found they were expressed in multiple tissue types, thus explaining the multi-organ involvement in infected patients observed worldwide during the ongoing pandemic.”
“With the launch of REVEAL: Single Cell, we support scientists in breaking through the complexities of working with massive single cell, multi-patient datasets,” added Marilyn Matz, co-founder and CEO of Paradigm4, in the press release. “Accelerating drug and biomarker discovery is a key driver for our customers. Our Agile Science engine, SciDB, with its REVEAL apps, transforms the way researchers integrate, share, and gain insights from multimodal scientific data.”
Source: Paradigm4
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Ensuring Quality from the Start: Raw Materials Testing Support
November 21st 2024Raw Materials are the foundation of every biopharma product. Our ultimate guide highlights how our testing support can help you establish purity, identity, and quality standards, ensuring a smooth manufacturing process and adherence to regulatory requirements.
Ensure the Safety of Allogeneic Therapies with Advanced qPCR Testing
November 21st 2024Elevate your viral screening with Eurofins BioPharma Product Testing’s qPCR- based assays. Our advanced testing goes beyond standard screenings to detect even dormant and hard-to-detect pathogens, ensuring comprehensive safety in every stage of the allogeneic therapy pipeline. Protect your products – and your patients- with industry-leading sensitivity and specificity.